Table 3.
CRS and HIPEC
| Author, year | Pat. [n] | Cytostatic agents (HIPEC) | Median OS [mths] | Median PFS [mths] | OS [%] | Survival CC-0/1 [%] |
|---|---|---|---|---|---|---|
| Pilati, 2003 [66] |
34 |
MMC/DDP |
18 |
- |
31 (2-y) |
- |
| Glehen, 2004 [67] |
53 |
MMC |
13 |
- |
32 (2-y) |
54 (2-y) |
| Glehen, 2004 [63] |
506 |
MMC/LOHP |
19 |
- |
39 (3-y) |
47 (3-y) |
| Shen, 2004 [68] |
77 |
MMC |
16 |
- |
25 (3-y) |
44 (3-y) |
| Verwaal, 03/08 [59,60] |
105 |
MMC |
22 |
12.6 |
28 (3-y) |
45 (5-y) |
| Quenet, ASCO 08 [69] |
37 |
LOHP/IRI |
37 |
13 |
- |
58 (3-y) |
| Elias, 2009 [46] |
48 |
LOHP |
63 |
- |
- |
51 (5-y) |
| Hompes, 2012 [65] | 48 | LOHP | - | 19.8 | - | 89 (2y) |